vs
Side-by-side financial comparison of ASCENT INDUSTRIES CO. (ACNT) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $11.9M, roughly 1.8× ASCENT INDUSTRIES CO.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -8.8%, a 16.0% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 13.3%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs -34.9%).
ASCENT INDUSTRIES CO.ACNTEarnings & Financial Report
Ascent Capital Group, Inc. was a publicly traded holding company whose primary subsidiary was Monitronics. Ascent Media was a wholly owned subsidiary of the Discovery Holding Company (DHC). DHC spun off Ascent Media as an independent, public company on September 17, 2008.
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
ACNT vs CUE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.9M | $21.9M |
| Net Profit | $-1.0M | $1.6M |
| Gross Margin | 14.6% | — |
| Operating Margin | -21.0% | 9.0% |
| Net Margin | -8.8% | 7.2% |
| Revenue YoY | 13.3% | 1292.3% |
| Net Profit YoY | -1.2% | 116.7% |
| EPS (diluted) | $-0.11 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.9M | $21.9M | ||
| Q3 25 | $19.7M | $2.1M | ||
| Q2 25 | $18.7M | $3.0M | ||
| Q1 25 | $24.7M | $421.0K | ||
| Q4 24 | $10.5M | $1.6M | ||
| Q3 24 | $20.9M | $3.3M | ||
| Q2 24 | $21.5M | $2.7M | ||
| Q1 24 | $28.0M | $1.7M |
| Q4 25 | $-1.0M | $1.6M | ||
| Q3 25 | $-2.1M | $-7.4M | ||
| Q2 25 | $6.3M | $-8.5M | ||
| Q1 25 | $-2.3M | $-12.3M | ||
| Q4 24 | $-1.0M | — | ||
| Q3 24 | $-6.2M | $-8.7M | ||
| Q2 24 | $-926.0K | $-10.2M | ||
| Q1 24 | $-5.5M | $-12.3M |
| Q4 25 | 14.6% | — | ||
| Q3 25 | 29.7% | — | ||
| Q2 25 | 26.1% | — | ||
| Q1 25 | 19.3% | — | ||
| Q4 24 | 24.3% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 13.1% | — | ||
| Q1 24 | 8.3% | — |
| Q4 25 | -21.0% | 9.0% | ||
| Q3 25 | -4.1% | -353.4% | ||
| Q2 25 | -14.4% | -292.3% | ||
| Q1 25 | -4.2% | -2921.4% | ||
| Q4 24 | -25.4% | — | ||
| Q3 24 | -9.4% | -264.2% | ||
| Q2 24 | -8.6% | -390.6% | ||
| Q1 24 | -15.5% | -737.8% |
| Q4 25 | -8.8% | 7.2% | ||
| Q3 25 | -10.6% | -346.6% | ||
| Q2 25 | 33.7% | -287.1% | ||
| Q1 25 | -9.3% | -2911.4% | ||
| Q4 24 | -9.8% | — | ||
| Q3 24 | -29.5% | -259.6% | ||
| Q2 24 | -4.3% | -382.7% | ||
| Q1 24 | -19.7% | -719.1% |
| Q4 25 | $-0.11 | $0.05 | ||
| Q3 25 | $-0.22 | $-0.07 | ||
| Q2 25 | $0.65 | $-0.09 | ||
| Q1 25 | $-0.23 | $-0.17 | ||
| Q4 24 | $-0.11 | — | ||
| Q3 24 | $-0.61 | $-0.17 | ||
| Q2 24 | $-0.09 | $-0.20 | ||
| Q1 24 | $-0.54 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $57.6M | $27.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $87.0M | $26.4M |
| Total Assets | $111.9M | $42.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $57.6M | $27.1M | ||
| Q3 25 | $58.0M | $11.7M | ||
| Q2 25 | $60.5M | $27.5M | ||
| Q1 25 | $14.3M | $13.1M | ||
| Q4 24 | $16.1M | $22.5M | ||
| Q3 24 | $8.5M | $32.4M | ||
| Q2 24 | $3.6M | $30.0M | ||
| Q1 24 | $1.3M | $41.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | $1.0M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $3.0M |
| Q4 25 | $87.0M | $26.4M | ||
| Q3 25 | $87.1M | $13.2M | ||
| Q2 25 | $89.7M | $18.2M | ||
| Q1 25 | $91.2M | $6.6M | ||
| Q4 24 | $93.5M | $17.5M | ||
| Q3 24 | $94.7M | $25.4M | ||
| Q2 24 | $101.0M | $21.6M | ||
| Q1 24 | $102.0M | $30.0M |
| Q4 25 | $111.9M | $42.2M | ||
| Q3 25 | $119.9M | $31.6M | ||
| Q2 25 | $122.6M | $40.7M | ||
| Q1 25 | $152.5M | $22.3M | ||
| Q4 24 | $147.3M | $32.2M | ||
| Q3 24 | $148.6M | $44.8M | ||
| Q2 24 | $158.2M | $42.3M | ||
| Q1 24 | $161.0M | $54.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.09× | ||
| Q1 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $266.0K | $-1.1M |
| Free Cash FlowOCF − Capex | $-196.0K | — |
| FCF MarginFCF / Revenue | -1.7% | — |
| Capex IntensityCapex / Revenue | 3.9% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | $-2.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $266.0K | $-1.1M | ||
| Q3 25 | $1.3M | $-9.0M | ||
| Q2 25 | $-1.4M | $-3.4M | ||
| Q1 25 | $-700.0K | $-8.2M | ||
| Q4 24 | $8.8M | $-36.3M | ||
| Q3 24 | $3.4M | $-7.5M | ||
| Q2 24 | $2.2M | $-10.0M | ||
| Q1 24 | $263.0K | $-9.8M |
| Q4 25 | $-196.0K | — | ||
| Q3 25 | $695.0K | — | ||
| Q2 25 | $-1.5M | $-3.4M | ||
| Q1 25 | $-1.0M | $-8.3M | ||
| Q4 24 | $8.4M | $-36.4M | ||
| Q3 24 | $3.1M | $-7.5M | ||
| Q2 24 | $1.9M | $-10.0M | ||
| Q1 24 | $25.0K | $-9.8M |
| Q4 25 | -1.7% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | -8.3% | -116.5% | ||
| Q1 25 | -4.1% | -1976.7% | ||
| Q4 24 | 80.6% | -2309.3% | ||
| Q3 24 | 15.1% | -225.7% | ||
| Q2 24 | 9.1% | -376.2% | ||
| Q1 24 | 0.1% | -573.0% |
| Q4 25 | 3.9% | 0.0% | ||
| Q3 25 | 3.1% | 0.0% | ||
| Q2 25 | 0.8% | 0.9% | ||
| Q1 25 | 1.3% | 35.6% | ||
| Q4 24 | 3.7% | 4.2% | ||
| Q3 24 | 1.3% | 0.0% | ||
| Q2 24 | 1.0% | 0.4% | ||
| Q1 24 | 0.9% | 3.2% |
| Q4 25 | — | -0.68× | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACNT
| Other | $6.1M | 52% |
| Transferred At Point In Time | $5.7M | 48% |
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
